|
|
|
| home > white papers > Accelerating the Time from DNA to Material - Merck |
|
|
 WHITE PAPERS |
|
Merck
|
|
Accelerating the Time from DNA to Material
|
|
Cell line development is a critical step in upstream process development
for monoclonal antibodies (mAbs). Unfortunately, the search for the
bestproducing clone can be labor- and resource-intensive and is often
compared with looking for a needle in a haystack. Cells must first be
engineered to produce the biologic of interest and the cell line
generated from a high producing clone must deliver a sufficiently high
titer to support clinical studies, and ultimately commercialization of
the therapeutic.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Sanofi, Capgemini, Generali and Orange announce the creation of a digital ecosystem dedicated to e-health, a first in Europe
Sanofi, Capgemini, Generali and Orange announce plans to create a joint venture in France to fast-track the development of concrete healthcare solutions and to make them available to the market for the benefit of patients. The project, on a scale that is unique in Europe, will bring together leading scientific and technological expertise in France and Europe. It will benefit from both a virtual platform and a physical base located in Paris, linked to the « PariSanté Campus » initiative announced by the French President and will strengthen the international positioning of France in digital health.
More info >> |
|
 |
White Papers |
 |
|
Case Study: Getting the Client’s Trust - Oncology Program
Cmed Clinical Services
Five years ago, a biopharmaceutical company chose Cmed to conduct a
phase II oncology study. Cmed’s performance of the study and the good
relationship established with the Client led Cmed to be awarded a second
oncology trial which a couple of years ago was followed by a third,
fourth and fifth.
More info >> |
|
 |
Industry Events |
 |
DIA Europe 2021
15-19 March 2021, VIRTUAL CONFERENCE
DIA Europe is the must-attend event for all life science professionals
working in drug development, from discovery to marketed use. It
encourages open collaboration by bringing together representatives from
the entire spectrum of the life science landscape and facilitating
crucial discussions across several topic tracks: Clinical Development,
Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy,
and many more.
More info >> |
|
|
|
